Top Markets
Coin of the day
Evommune, Inc. Evommune, Inc.

Evommune, Inc.

EVMN
Rank in Stocks #13758
Evommune, Inc. is a United States-based clinical-stage biotechnology company... Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Share Price
$12.78
Market Cap
$463.81M
Change (1 day)
-2.07%
Change (1 year)
-
Country
US
Trade Evommune, Inc. (EVMN)

Category

Number of shares outstanding for Evommune, Inc. (EVMN)
Number of shares outstanding as of August 2026: 0
According to Evommune, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Evommune, Inc. (EVMN) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
62.19M -
NL
478.91M -
AU
396.00M -
US
- -
CH